Author

A. Biji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

O. Khatun· 2 shared R. Narayan· 2 shared S. Tripathi· 2 shared A. Singh· 1 shared C. D. Rao· 1 shared D. Gupta· 1 shared D. K. Saini· 1 shared D. Satish· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

O. Khatun

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models.

R. Narayan, M. Sharma, R. T. Yadav, A. Biji, O. Khatun, R. S. Rajmani, P. R. Sharma, S. Jeyashankar, P. Rani, C. D. Rao, V. Satchidanandam, S. Das, R. Agarwal, S. Tripathi

This paper identifies picolinic acid as a broad-spectrum antiviral that inhibits enveloped virus entry, showing efficacy against SARS-CoV-2 and Influenza A Virus in animal models.

bioRxiv · Feb 16, 2022 · PreprintMicrobiology

Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples

A. Biji, O. Khatun, S. Swaraj, R. Narayan, R. Rajmani, R. Sardar, D. Satish, S. Mehta, H. Bindhu, M. Jeevan, D. K. Saini, A. Singh, D. Gupta, S. Tripathi

This study identifies prognostic markers and therapeutic targets for COVID-19 by analyzing Omics data from nasal and BALF samples, finding S100 family genes and TXN as key factors, and validating Auranofin as a potential treatment.

bioRxiv · Feb 18, 2021Microbiology